Understanding the Role of Anti-68kDa Neurofilament/NF-L Antibody [NFL/736] in Neurological Research

The Anti-68kDa Neurofilament/NF-L antibody [NFL/736] is a specialized monoclonal tool utilized in biomedical research to detect the light chain of neurofilaments, a critical structural protein found in neurons. Developed for high-specificity binding, this mouse-derived IgG1 antibody is frequently employed in laboratory settings to study neurodegenerative conditions and axonal integrity. Researchers often utilize this specific clone, [NFL/736], to map the distribution of 68kDa neurofilament light (NF-L) proteins across various tissue samples, providing a clearer picture of neuronal health at the molecular level.

Specifications and Technical Profile of Clone NFL/736

According to standard laboratory documentation for the [NFL/736] clone, the antibody is produced in a mouse host and categorized as a monoclonal IgG1 isotype. A significant feature for researchers is that the product is provided in a carrier-free format, meaning it is formulated without Bovine Serum Albumin (BSA) or sodium azide. This composition is particularly advantageous for applications such as direct labeling or conjugation, where the presence of extraneous proteins or preservatives might otherwise interfere with downstream experimental protocols.

The 68kDa neurofilament light chain (NF-L) serves as a primary marker in the cytoskeleton of neurons. By targeting this specific protein, the [NFL/736] antibody allows scientists to visualize structural changes within nerve fibers. The use of a monoclonal antibody ensures a high degree of consistency, as the clone is derived from a single cell line, providing a uniform affinity for the NF-L antigen across different batches of research.

Applications in Neurodegenerative Research

Neurofilaments are increasingly recognized as sensitive biomarkers for axonal damage. When neurons are injured or undergo degeneration, neurofilament proteins are released into the extracellular space and eventually into the cerebrospinal fluid or blood. By utilizing the [NFL/736] antibody in techniques such as Western blotting, immunohistochemistry, or immunocytochemistry, investigators can quantify the presence and localization of these proteins.

The antibody’s specificity for the 68kDa subunit makes it a precise instrument for identifying the structural integrity of the cytoskeleton. Because the antibody is supplied without BSA or azide, it is compatible with a wider array of sensitive detection methods. Researchers often prefer this “carrier-free” configuration when conducting high-throughput screening or developing custom diagnostic assays where the chemical environment of the antibody must be strictly controlled to prevent background interference.

Technical Considerations for Laboratory Use

When incorporating the [NFL/736] antibody into experimental workflows, technical teams must account for the specific handling requirements associated with monoclonal, carrier-free reagents. Unlike polyclonal antibodies, which may recognize multiple epitopes, the monoclonal nature of this antibody provides high specificity but requires optimized buffer conditions to maintain binding efficacy. The absence of sodium azide—a common preservative that can inhibit certain enzymatic reactions—renders this reagent suitable for live-cell studies or sensitive conjugation processes, provided that proper sterile handling techniques are maintained to prevent microbial contamination.

Researchers are advised to verify the compatibility of the [NFL/736] clone with their specific secondary detection systems, such as fluorescently labeled anti-mouse IgG. As with all monoclonal antibodies, the concentration and storage conditions—typically involving stable, low-temperature environments—are critical to ensuring the longevity and performance of the reagent over the course of a long-term study.

Ongoing Developments in Neurofilament Analysis

The field of neurofilament research continues to evolve, with increasing focus on the development of ultra-sensitive detection platforms. The use of well-characterized antibodies like [NFL/736] remains a foundational element in these efforts. As the scientific community refines its understanding of how NF-L levels correlate with disease progression in conditions involving central nervous system injury, the availability of purified, carrier-free monoclonal antibodies supports the reproducibility of these critical findings.

For laboratories looking to implement this antibody in their existing protocols, the next checkpoint involves validating the antibody against the specific tissue or cell line model being studied. Researchers typically perform titration experiments to determine the optimal dilution factor, ensuring that the signal-to-noise ratio is sufficient for accurate quantification in their specific experimental design.

For further information on experimental protocols and compatibility documentation for the [NFL/736] clone, researchers should consult the technical datasheets provided by the manufacturer, Abcam, or review relevant peer-reviewed literature regarding neurofilament immunodetection techniques.